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INTRODUCTION
Schizophrenia is not an uncommon disease. According to
World Health Organization (WHO), approximately 29
million people suffer from the disease worldwide (1). More-
over, it has been reported that schizophrenia affects 0.7% of
the U.S. population (2), and that the lifetime prevalence of
schizophrenia in Korea is 0.28% (3). 
Schizophrenia is a chronic, debilitating condition with a
lower mortality than many other chronic illnesses. Howev-
er, it has been reported that schizophrenia is a costly disease
(4, 5), and that costs associated with productivity losses are
probably the largest component of the overall societal cost
of schizophrenia (4). Therefore, the adequate distribution of
medical resources and the establishment of proper healthcare
policies are crucially required to effectively manage this ill-
ness. For this reason, it is critical that the economic burden
of schizophrenia can be measured from a societal perspective.
Only one Korean study has reported that schizophrenia is
a relatively costly illness, as compared with coronary heart
disease, but this study was limited to outpatients at one hos-
pital (6). The costs of schizophrenia have never been estimat-
ed in Korea from a societal perspective, and therefore, a com-
prehensive estimate of the costs associated with this disease
was required to ensure the efficient and systematic delivery
of an appropriate mental health service.
The aims of this study were to estimate the prevalence of
treated schizophrenia in Korea in 2005 and to determine
the direct and indirect costs associated with the disease.
MATERIALS AND METHODS
Estimates of total societal costs were based on treated preva-
lence. Initially, the treated prevalence rate of schizophrenia
in 2005 was estimated based on information from the ‘‘Statis-
tical Information System of National Health Insurance’’ (7),
the ‘‘National Health Insurance Statistical Yearbook’’ (8),
and the ‘‘Medical Aid Statistical Yearbook’’ (9). Information
on the 2005 general population was obtained from the Kore-
an National Statistical Office (10). The Korean Medical Secu-
rity system consists of National Health Insurance and Med-
ical Aid. The majority of Koreans are beneficiaries of Nation-
al Health Insurance, and people at the lowest income level
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Economic Burden of Schizophrenia in South Korea
This study estimates the treated prevalence of schizophrenia and the annual costs
associated with the illness in Korea in 2005, from a societal perspective. Annual
direct healthcare costs associated with schizophrenia were estimated from Nation-
al Health Insurance and Medical Aid records. Annual direct non-healthcare costs
were estimated for incarceration, transport, community mental health centers, and
institutions related to schizophrenia. Annual indirect costs were estimated for the
following components of productivity loss due to illness: unemployment, reduced
productivity, premature mortality, and caregivers’ productivity loss using a human
capital approach based on market wages. All costs were adjusted to 2005 levels
using the healthcare component of the Consumer Price Index. The treated preva-
lence of schizophrenia in 2005 was 0.4% of the Korean population. The overall
cost of schizophrenia was estimated to be $ 3,174.8 million (3,251.0 billion Won),
which included a direct healthcare cost of $ 418.7 million (428.6 billion Won). Total
direct non-healthcare costs were estimated to be $ 121 million (123.9 billion Won),
and total indirect costs were estimated at $ 2,635.1 million (2,698.3 billion Won).
Unemployment was identified as the largest component of overall cost. These find-
ings demonstrate that schizophrenia is not rare, and that represents a substantial
economic burden.
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analyze every case of schizophrenia treated in Korea.
Estimations of the costs of schizophrenia vary between
countries due to different healthcare systems, but the com-
monly accepted definitions of costs related to illness are as
follows. Cost-of-illness (COI) studies identify two main cat-
egories of cost: 1) direct costs, for which payments are made,
and 2) indirect costs, for which resources are lost (5).
In the present study, we used various data sources, includ-
ing published scientific literature and government reports
and documents to estimate the economic burden of schizo-
phrenia. The focus of our literature review was on Korean
data sources, especially on government reports. When Kore-
an data sources were not available, data from COI studies on
schizophrenia in other countries were used. However, this
was limited to data about the prevalence rate of schizophre-
nia among all suicide victims. 
Where possible, all resource utilization estimates were
obtained for 2005, and these were expressed in 2005 U.S.
dollars (average exchange rate 1 U.S. Dollar=1,024 Korean
Won as of 2005, Korean Exchanging Bank). When costs
were unavailable for 2005, the healthcare component of the
Korean Consumer Price Index (CPI) was used to adjust costs
to 2005 values (10).
Costs included in this analysis were; direct healthcare costs,
direct non-healthcare costs, and the indirect costs associated
with productivity losses. The methods used to determine
costs in each category are described below. 
Direct health care costs
Patients included in our analyses were defined as those
with an F20 diagnosis (ICD-10 diagnosis code). We obtained
details on overall healthcare utilization in Korea from the
previously mentioned database and Yearbooks (7-9), which
also contained information on total numbers of outpatients
and inpatients, and the cost of total visits and total admis-
sions. Total outpatient cost-National Health Insurance and
Medical Aid-was divided by the number of patients to deter-
mine per-person outpatient cost, and the same procedure
was followed for inpatients.
Direct non-healthcare costs
We defined direct non-healthcare costs as costs related to
patient management, excluding medical care costs. Direct
non-healthcare costs were estimated for the criminal justice
system, community mental healthcare centers, sanatoria,
rehabilitation facilities, homeless shelters, and transport costs
related to schizophrenia.
The crime rate among persons with severe mental illness
is higher than in the general population (11). Cost estimates
relating to the criminal justice system were mainly incarcer-
ation costs related to schizophrenia. Costs associated with
crime are debatable, because policing, investigations, legal
defense, and prosecution costs could all arguably be includ-
ed in calculations of the economic burden of schizophrenia.
However, there were no data on these detailed contents. In
the present analysis, we focused on areas with available defini-
tive data, such as the cost of incarceration. The Korean gov-
ernment has operated a cure-custody system since 1980,
and the Institute of Forensic Psychiatry Ministry of Justice
is responsible for providing mentally disordered offenders
with treatment in custody. We calculated incarceration costs
associated with schizophrenia using estimates supplied by the
annual budget of the Institute of Forensic Psychiatry Min-
istry of Justice (12) and the incarceration rate. A recent study
by the Institute of Forensic Psychiatry Ministry of Justice
reported that persons with schizophrenia accounted for 55%
of incarcerated offenders (13). 
In 2005, there were 127 community mental health cen-
ters, which provided mentally ill patients in communities
with mental health programs. Annual budgets, operating
programs, and schizophrenia registration rates were avail-
able from the government report, ‘‘2005 The Central Men-
tal Health Supporting Committee Report’’ (14). This report
also contains comprehensive information about sanatoria and
rehabilitation facilities. Annual operating cost and percent-
age of schizophrenia according to institution type were also
obtained from this report.
In 2005, there were 38 homeless shelters nationwide that
admitted mentally ill patients. Nine thousands and fifty five
persons were registered at homeless shelters in 2005 (15),
and of these 62% were diagnosed as having schizophrenia
(3). The majority of these homeless shelters were adminis-
tered by the private sector. Thus, we were unable to obtain
the total annual operation costs associated with schizophre-
nia at homeless shelters due to limited accessibility to private
data. Therefore, to estimate the cost related to schizophrenia
in homeless shelters, we use the standardized operation fee
model proposed by the Korean Institute of Health and Social
Affairs (KIHASA) (16), which suggested that an average of
$3,500 per person per annum is required to maintain a
homeless shelter.
Transport costs were estimated by multiplying the num-
ber of total visits to outpatient clinics by the mean return
fare, and it has been reported that the mean return fare per
visit is $5.5 (6).
Indirect costs: productivity losses
Productivity losses caused by schizophrenia can be divid-
ed into productivity losses associated with morbidity and
those associated with premature mortality. Schizophrenia
morbidity increases unemployment and reduces productivi-
ty. Morbidity costs also include productivity losses by patients
and their caregivers due to illness. Mortality costs were defin-
ed as the product of the number of deaths due to schizophre-
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Thus, indirect annual costs resulting from schizophrenia
were estimated separately for four distinct components of
productivity loss: 1) increased unemployment; 2) reduced
workplace productivity due to morbidity; 3) premature mor-
tality resulting from schizophrenia; and 4) care-giving time
required of family member. Indirect costs due to schizophre-
nia were estimated using a human capital method, i.e., by
multiplying the expected mean earnings of an individual
without illness by time lost at work. The equations used to
estimate indirect costs are presented in Appendix 1.
First, a review of published studies determined that the
estimated employment-to-population rate of schizophrenia
was 18.8% (from 15.9% to 21.7%) in Korea (6, 17, 18).
This rate was lower than the employment-to-population
rate for the general population in 2005 (59.7%) (10). The
resultant productivity loss due to unemployment was esti-
mated as lost earnings due to morbidity in the schizophre-
nia population using the mean annual wage for 2005, as
reported by the Korean Ministry of Labor for the employed
population (19). 
Second, employed persons with schizophrenia have reduced
productivity resulting from disability due to illness. Produc-
tivity reductions were estimated from average earnings in
the general population and productivity reduction ratios.
Productivity reduction ratios were calculated by subtracting
population-to-patient earning ratios from ‘1’. The average
income of employed persons with schizophrenia is about
40% (range from 30% to 50%) of that of the general popu-
lation in Korea (6, 18).
Third, the present value of lost earnings due to premature
mortality (20) was calculated from deaths attributable to
schizophrenia and annual earnings, data for these calcula-
tions were obtained from the National Mortality Statistics
(10) and the Ministry of Labor (19). Only persons with schi-
zophrenia who died when less than 65 yr old were included
in this analysis, although this figure is lower than the recog-
nized retirement age in South Korea, it was intentionally
adopted in order to ensure that the study results were con-
servative. The average retirement age was 68.2 for men and
66.9 for women in 2004 (Korea Labor Institute). Expected
future earnings lost due to premature mortality among per-
sons with schizophrenia were adjusted to 2005 values using
a 3% discount rate. Information on numbers of deaths due
to schizophrenia or suicides per year in Korea was obtained
from National Mortality Statistics. However, suicide is the
most common cause of premature deaths in schizophrenia (17).
Therefore, the cause of death from schizophrenia in Nation-
al Mortality Statistics can underestimate the total number
of deaths from schizophrenia, because a proportion of deaths
coded as ‘suicide’ can result from schizophrenia. A review of
the literature suggested that the prevalence of schizophrenia
among suicide victims ranged from 2% to 12% (21). For
this study, we assumed that 7% of all Korean suicides were
attributable to schizophrenia. To estimate productivity losses
associated with premature mortality, we combined estimates
of mortality due to schizophrenia by age and gender with
estimates of labor force income data for those employed.
Finally, the costs of caregiver productivity losses were esti-
mated using family member’s productivity loss and the mean
monthly wages of employed individuals in 2005 (19). It was
reported that 24.9% of schizophrenia patients with disabili-
ty (estimated as 24,015 in 2005) interfere with the earning
capacity of caregivers on a daily basis (18), and therefore esti-
mated that the number of such schizophrenia patients was
5,980/day in 2005.
In the present study, a human capital method was used to
estimate indirect societal costs associated with unemployment
and reduced productivity. Some patients with schizophrenia
are provided with disability payments and other forms of
governmental support, and although these payments are made
as a result of schizophrenia morbidity, they do not reflect
true societal costs because these resources simply represent
transfers from some members of society to others (i.e., trans-
fer payments) (4, 22). In the present study, indirect schizophre-
nia costs were estimated based on the standpoint ‘of likely
earnings in the absence of illness’. Thus, governmental sup-
port costs were excluded from our indirect cost calculations.
Total cost estimates and sensitivity analyses 
Although resource utilizations and unit cost information
were obtained directly from National Health Insurance
records, direct healthcare costs are also influenced by self-
payments made due to Health Insurance exclusions, and
average exclusion payments ranged from 11% to 20% (23).
To assess the robustness of cost estimates made during this
analysis, sensitivity analyses were conducted. Cost estimates
were set at the lowest and highest levels reported in the lit-
erature, respectively, whilst other parameters were held con-
stant. Productivity loss estimates were based upon literature
estimates, and these rates and costs were also subjected to
sensitivity analysis. More specifically, we evaluated the sen-
sitivity of schizophrenia total cost estimates with respect to
exclusion payment rates (11% and 20%), alternative discount
rates (0% and 5%) of expected future earning, schizophre-
nia employment rates (15% and 22%), productivity reduc-
tion ratios (0.5 and 0.7), and prevalence of schizophrenia
among all suicides (2% and 12%).
Most of COI studies associated with schizophrenia were
based on human capital approach (5). A different perspec-
tive on mortality cost estimates is offered by Goeree et al. (20),
who used the friction cost method instead of using human
capital approach. We also estimated the productivity costs
associated with schizophrenia premature mortality by using
the friction cost method. Sensitivity analysis was conducted
on friction periods required for worker replacement.
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Treated prevalence of schizophrenia in Korea
The treated prevalence rate of schizophrenia in the Kore-
an population in 2005 was 0.4% (Table 1). The number of
persons treated with schizophrenia in 2005 was 161,058
(89,720 men and 71,339 women). Table 1 also shows treat-
ed prevalence rates of schizophrenia among the total popu-
lation in 2005 by gender and age group.
Direct cost of schizophrenia
Fig. 1 presents individual direct costs as a percentage of
total direct cost. 
Direct healthcare costs
The total direct health care cost for individuals with schi-
zophrenia in 2005 was estimated to be $418.7 million (428.7
billion Won), or 13.2% of the total costs associated with
schizophrenia. Table 3 shows the proportions of direct health
care costs attributable to inpatient and outpatient care based
on information provided by Medical Security Systems. Pati-
ent-level costs for individuals that received National Health
Insurance and Medical Aid are also presented in Table 3. 
The average length of stay for patients with schizophrenia
enrolled with National Health Insurance was 99 days and
for Medical Aid patients this was 234 days. In terms of all
inpatients regardless of disease entity in 2005, average length
of stay was 14 days (Health Insurance) and 71 days (Medical
Aid). Total annual national health care expenditure on med-
ical care in Korea in 2005 was U.S. $25.8 billion (43.0%
on outpatient care, and 30.4% on inpatient care). The direct
health care costs of schizophrenia accounted for 1.6% of
national health care expenditure in 2005, and the inpatient
care cost of schizophrenia contributed 78.3% to the direct
health care costs of schizophrenia.









-19 2,238 0.1 1,658 0.1 3,896 0.1
20-29 11,153 0.3 8,429 0.2 19,583 0.3
30-39 27,245 0.7 19,956 0.5 47,201 0.6
40-49 26,319 0.7 21,170 0.5 47,489 0.6
50-59 13,399 0.5 10,860 0.4 24,259 0.5
60-64 3,409 0.4 3,185 0.3 6,593 0.3
65+ 5,956 0.3 6,081 0.2 12,038 0.3
Total 89,720 0.4 71,339 0.3 161,058 0.4
Table 1. Treated prevalence rate of schizophrenia in South Korea
Sources: National Health Insurance Statistical Yearbook (7, 8), Medical
Aid Statistical Yearbook (9), Korean National Statistical Office (10).
Type of cost Cost, $ (in million)* %
Direct costs 539.7 17.0
Direct healthcare costs 418.7 13.2
Outpatient care costs 77.7  2.4
Inpatient care costs 327.7 10.3
Pharmacy costs 13.3 0.4
Direct non-healthcare costs 121.0 3.8
Incarceration 8.5 0.3
Community mental healthcare centers 11.3 0.4
Sanatoria 62.2 2.0
Rehabilitation facilities 8.4 0.3
Homeless shelters 23.2  0.7
Transport costs 7.4  0.2
Indirect costs 2,635.1  83.0
Unemployment 1,798.2 56.6
Reduced productivity at work 431.1  13.6
Premature mortality 273.6  8.6
Caregiver productivity loss 132.2  4.2
Total costs of schizophrenia in 2005 3,174.8 100
Table 2. Overall costs of schizophrenia in South Korea
*Average exchange rate 1 U.S. Dollar=1,024 Korean Won in 2005.
Health insurance Medical aid
Total direct healthcare costs $ 161.1 million $ 257.6 million
Outpatient care $ 54.7 million $ 23.0 million
Inpatient care $ 94.4 million $ 233.3 million 
Pharmacy $ 12.0 million $ 1.3 million
Healthcare cost per patient
Outpatient care $ 635 $ 509
Inpatient care $ 4,389 $ 6,510
Average length of stay 99 days 234 days
Table 3. Direct healthcare costs and in-patient durations in South
Korea
Average exchange rate 1 U.S. Dollar=1,024 Korean Won in 2005.
Sources: National Health Insurance Statistical Yearbook (7, 8), Medical

















Fig. 1. Direct costs for patients with schizophrenia in South Korea
($ 539.7 million).Direct non-health care costs
Direct non-healthcare costs were estimated to be $121.0
million (123.9 billion Won) in 2005 for schizophrenia-relat-
ed incarceration, community mental health centers, institu-
tions, and transport (Table 2). These costs represent 3.8% of
the total costs associated with schizophrenia. Schizophrenia-
related incarceration contributed $8.5 million (8.7 billion
Won) to the total annual cost of schizophrenia. The institu-
tions that deal with schizophrenics, i.e., sanatoria, rehabili-
tation facilities and homeless shelters, contributed $93.8 mil-
lion (96.0 billion Won) to the annual cost imposed by the
disease. Transport cost for visits to outpatient departments
contributed $7.4 million (7.6 billion Won) to the annual
cost of schizophrenia.
Indirect costs
Fig. 2 shows individual indirect costs as a percentage of
total indirect costs. 
Morbidity costs
Assuming a mean employment rate of persons with schi-
zophrenia of 18.8%, additional productivity losses due to
unemployment were calculated and results are presented in
Table 4. Overall increased unemployment due to schizophre-
nia resulted in a cost of $1,798.2 million (1,841.4 billion
Won), and this was the largest contributor to total indirect
costs. In terms of employed schizophrenia, the productivity
reduction ratio was calculated to be ‘0.6’, and thus, reduced
productivity at work cost $431.1 million (441.4 billion Won)
(Table 4).
Mortality costs
The number of deaths in 2005 listed as being due to schi-
zophrenia and the numbers of suicides attributed to schizo-








-29 89.9 66.1 23.9 18.0
30-39 645.6 160.6 100.7 53.0
40-49 589.7 183.4 114.0 46.9
50-59 56.4 18.6 50.7 20.7
60+ 23.2 7.4 8.3 4.8
Table 4. Additional unemployment and reduced productivity
costs in South Korea, by age and gender
*Average exchange rate 1 U.S. Dollar=1,024 Korean Won in 2005.
Sources: Korean National Statistical Office (10), Labor Statistics of












-19 -- 98 9 8
20-29 2 2 50 45 52 47
30-39 8 9 87 48 95 57
40-49 20 12 122 43 142 55
50-59 21 9 95 28 116 37
60-64 5 7 50 17 55 24
65+ 22 21 149 89 171 110
Table 5. Premature mortality attributable to schizophrenia in
South Korea, by age and gender
Sources: Korean National Statistical Office (10), Goeree et al. (21).
Assumption Cost ($ millions)*
Base case 3,174.8












Prevalence of schizophrenia in suicides
0.2% 3,001.1
0.7% 3,348.8





Table 6. Sensitivity analysis on key burden of illness assumptions
*Average exchange rate 1 U.S. Dollar=1,024 Korean Won in 2005; 
� Mor-











Fig. 2. Indirect costs for patients with schizophrenia in South Korea
($ 2,635.1 million).phrenia are presented in Table 5. The 138 deaths were list-
ed as being due to schizophrenia (78 males and 60 females),
and 840 suicides were attributed to schizophrenia (562 males
and 278 females). Thus, the total estimated number of deaths
due to schizophrenia in 2005 was 978, of which 640 were
males and 338 were females. Additionally costs due to pre-
mature mortality were estimated at $273.6 million (280.2
billion Won) (estimated by applying a 3% discount rate).
Caregivers’ costs
Concerning schizophrenia patients with disabilities, aver-
age 5,980 schizophrenics per day required cares from their
family members to the extent that these interfered with care-
givers’ earnings. Patients admitted by institutions were not
included in this estimate. The total cost associated with care-
giver productivity losses was $132.2 million (135.4 billion
Won).
Sensitivity analysis
Base case COI estimates and the results of selected sensi-
tivity analyses are presented in Table 6. Assuming that addi-
tional self-payments due to exclusion from National Health
Insurance contribute to direct health care costs, total cost
estimates, including self-payment rates, were $3,370.3 and
3,386.1 million when additional self-payment rates were
assumed to be 11% and 20%, respectively. The results accord-
ing to varying unemployment rate assumptions for schizo-
phrenia showed that the results were $3,309.8 million (em-
ployment rate 15%) and $3,061.8 million (employment rate
22%). The use of a 0% discount rate increased total schizo-
phrenia cost to $3,290.8 million, and a 5% discount rate
reduced this to $3,126.8 million. When a 0.5 productivity
reduction ratio was used, total schizophrenia cost reduced to
$3,101.8 million, and for a ratio of 0.7 total cost increased
to $3,248.8 million. We varied the schizophrenia prevalence
rate in all suicides using the range from 2% to 12%. Appli-
cation of the lower (2%) and upper bound (12%) values in
this analysis resulted in total schizophrenia cost of $3,001.1
million and $3,348.8 million, respectively. Finally, assum-
ing a 1- or 6-month friction period for worker replacement,
the productivity costs associated with premature death were
estimated at $0.8 million and $4.7 million, respectively.
Therefore, the total schizophrenia cost was estimated at
$2,902.0 (1-month friction period) and $2,905.9 million
(6-month friction period).
DISCUSSION
Schizophrenia follows a chronic debilitating course, and
thus, its costs tend to persist. Estimated prevalences of schi-
zophrenia vary by country and time, and it has been estimat-
ed that the lifetime prevalence rate of schizophrenia lies bet-
ween 0.4% and 0.7% (2, 24). According to the 2001 Kore-
an Epidemiologic Catchment Area (KECA) Study, the one-
year prevalence rate of schizophrenia among community res-
ident adults aged 18-64 yr is 0.16% (25), and when persons
living in institutions were included, the one year prevalence
rate increased to 0.28% (3). In the present study, the treated
prevalence rate of schizophrenia was 0.4%, which was found
to be higher than the prevalence rates in the previous epi-
demiologic studies in Korea. Our estimation of the preva-
lence of schizophrenia was based on claims data (7-9), which
are supported by diagnoses made by psychiatrists. This ob-
served difference in the prevalence of schizophrenia supports
the notion that clinical interviews by clinicians are more
useful than structured interviews by trained laymen (2, 24).
It also indicates that the Composite International Diagnos-
tic Interview (CIDI) is not sensitive enough to estimate the
prevalence of psychotic disorders (25), and that a clinical re-
interview is required for all epidemiologic survey respon-
dents suspected of having psychotic symptoms (26).
The costs of schizophrenia have been estimated in a num-
ber of countries (27), e.g., Australia, Belgium, Canada, Den-
mark, France, Germany, Italy, Norway, Puerto Rico, Spain,
Sweden, Taiwan, the United Kingdom, and the United States.
However, no previous study has estimated the economic bur-
den of schizophrenia in Korea. Therefore, we compared out
results with those published in other countries. Despite dif-
ferences in data sources and costing methodologies, the im-
pact of schizophrenia on health care expenditure is univer-
sally substantial. Moreover, direct cost estimates of schizo-
phrenia across countries are remarkably similar, and range
from 1.5% to 3% of national healthcare expenditure (5, 22).
Our study shows that direct healthcare costs accounted for
around 1.6% of total health care expenditure in Korea, which
compares favorably to cost estimates made in other countries.
Inpatient care is the single largest contributor to the direct
healthcare costs of schizophrenia. In terms of cross-national
comparisons, inpatient care costs account for the largest pro-
portion of direct healthcare costs in most countries. The pro-
portion of cost attributed to inpatient care varies between
countries, as it is a function of individual mental health deliv-
ery systems. Generally between 33% and 66% of total health-
care costs for schizophrenia are for inpatient care, even in
countries that have already substantially reduced their inpa-
tient provisions (5). In the present study, it was found that
inpatient care costs associated with schizophrenia accounted
for 78.3% of the total health care costs for schizophrenia in
Korea, which is higher than has been reported in other coun-
tries. This level of inpatient care cost is also higher than the
30.4% of total national healthcare costs spent on inpatients
in Korea.
Average length of stay of schizophrenia was longer than
other diseases. In Korea the number of psychiatric beds has
continuously increased from the 1980’s; in fact this rate of
increase is higher than in any other OECD member nation
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predominantly treated by hospitalization in Korea, and that
mean length of stay is greater than in other countries (14,
28-30).
The costs associated with psychosocial rehabilitation like
community mental healthcare centers and rehabilitation
facilities are 0.7%, which was much lower than the other
costs of schizophrenia.
These findings - inpatient oriented treatment, long length
of stay, poor psychosocial treatment - indicate that more atten-
tion should be paid to activities like de-institutionalization,
community-based mental healthcare, and psychosocial reha-
bilitation. Moreover, psychosocial rehabilitation in commu-
nity will decrease the productivity loss due to schizophrenia.
Studies on schizophrenia costs vary considerably in terms
of productivity cost estimates, especially with respect to indi-
rect costs (4, 5, 22). These differences are largely due to the
inclusion, or not, of premature mortality and morbidity pro-
ductivity estimates in cost calculations, and whether produc-
tivity was determined using the human capital approach or
the friction cost method (20), the latter of which allows for
the possibility of worker replacement (the number of days
necessary to fill the vacant position). 
The majority of studies that have addressed the costs asso-
ciated with productivity losses and indirect costs have report-
ed that productivity losses outweigh direct healthcare costs
(4, 5, 22), whereas a smaller number of studies have conclud-
ed to the contrary (5). However, most studies have found that
productivity losses are 2.0 times higher (ranging from one
to seven times higher) than direct health care costs. Accord-
ing to our cost estimates, indirect costs are 4.8 times larger
than direct costs. Unemployment was found to be the largest
contributor to the costs related to schizophrenia, which is a
reflection of the fact that schizophrenia morbidity is associ-
ated with a continued inability to work. Caregivers’ produc-
tivity losses contributed least to indirect costs in the present
study, which is unlike that found by other studies (4, 5).
Schizophrenia patients under inpatient care were excluded
from the caregivers’ productivity loss estimate. Therefore,
our findings suggest that the relatively low number of care-
givers were interfered with their productivity losses due to
high proportion of inpatient care in Korea.
Some factors may have resulted in under-estimations dur-
ing our analysis of COI. First, we did not include costs asso-
ciated with distress, pain, and an impoverished quality of
life, which are not measurable. Second, we did not include
cost estimates for over-the-counter or herbal medications.
Third, we did not include cost estimates for outpatient wait-
ing time, and time spent visiting hospitals.
In summary, the treated prevalence rate of schizophrenia
in Korea in 2005 was 0.4%. Using this prevalence-based
COI estimate, the cost of schizophrenia in Korea in 2005
was estimated to be $3,174.8 million, and of this, $539.7
million was accounted for by healthcare and non-healthcare
costs, and $2,635.1 million by productivity losses related
to morbidity, premature mortality, and caregivers’ produc-
tivity losses. Inpatient care was found to be the single largest
contributor to direct healthcare costs, whereas psychosocial
rehabilitation costs were found to be too low. The greatest
contributor to the cost of schizophrenia in Korea was iden-
tified as a high level of unemployment. These findings indi-
cate that more action must be taken to de-institutionalize
mental healthcare, and that programs should be targeted at
improving psychosocial rehabilitation.
REFERENCES
1. World Health Organization. Mental and neurological disorders. Fact
sheet no. 265. 199; Available from: http://www.who.int/whr/2001/
media_centre/en/whr01_fact_sheet1_en.pdf
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Esh-
leman S, Wittchen HU, Kendler KS. Lifetime and 12-month preva-
lence of DSM-III-R psychiatric disorders in the United States. Results
from the National Comorbidity Survey. Arch Gen Psychiatry 1994;
51: 8-19.
3. Cho SJ, Cho MJ, Suh T, Hahm BJ, Hong JP, Bae JN, Lee JY, Lee
DW, Park JI, Jeon HJ, Kim SJ, Kim YI. Prevalence rates of major
mental disorders in mental health related facilities: nationwide 20 insti-
tutions study. J Korean Neuropsychiatr Assoc 2004; 43: 749-59.
4. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M,
Aggarwal J. The economic burden of schizophrenia in the United
States in 2002. J Clin Psychiatry 2005; 66: 1122-9.
5. Knapp M, Mangalore R, Simon J. The global costs of schizophre-
nia. Schizophr Bull 2004; 30: 279-93.
6. Park JI, Song SH, Suh Tw, Jang HJ, Lee JG, Chang AK, Kim Y, Lee
C, Hong JP. Direct and indirect cost of treating out-patients with
schizophrenia in Korea. J Korean Neuropsychiatr Assoc 2000; 39:
580-8.
7. National Health Insurance Corporation. Statistical Information Sys-
tem. National Health Insurance Corporation 2007 April cited; Avail-
able from: http://www.nhic.or.kr/wbm/wbmb/wbmb_1000_f.jsp.
8. Health Insurance Review Agency, National Health Insurance Corpo-
ration. 2005 National Health Insurance Statistical Yearbook. Seoul,
Korea: Health Insurance Review Agency and National Health Insur-
ance Corporation 2006.
9. Ministry of Health and Welfare, National Health Insurance Corpora-
tion. 2005 Medical Aid statistical Yearbook. Seoul Korea: Ministry
of Health and welfare and National Health Insurance Corporation
2006.
10. Korean National Statistical Office. Korean Statistical Information
System. Korean National Stastical Office 2007 April cited; Avail-
able from: http://kosis.nso.go.kr/
11. Bonta J, Law M, Hanson K. The prediction of criminal and violent
recidivism among mentally disordered offenders: a meta-analysis.
Psychol Bull 1998; 123: 123-42.
12. The National Assembly of the Republic of Korea. National Budget
and Settlement of Accounts Information System. The National Assem-
Cost of Schizophrenia in Korea 173bly of the Republic of Korea 2007 April cited; Available from: http:
//nafs.assembly.go.kr:83/
13. Jeong PJ. A study on the cure-custody system for mentally disordered
offenders. Kongju: Kongju National University; 2004.
14. Suh TW, Cho MJ, Kim JH, Kwak YS, Kim KK, Bae A, Kim DH.
2005 The Central Mental Health Supporting Committee Report. Min-
istry of Health and Welfare, Korean Institute for Health and Social
Affairs, Central Mental Health Supporting Committee 2006.
15. Ministry of Health and Welfare. Statistical Data; statistics of home-
less shelter Ministry of Health and Welfare 2007 April cited; Avail-
able from: http://www.mohw.go.kr/
16. Kim MS. Development of a standardized operation fee model for
social welfare facilities. Health and welfare policy forum 2003; 84:
88-101.
17. Hong JP, Kim CY. Course and Outcome of Schizophrenia. Korean
J Psychopathol 1999; 8: 140-50.
18. Ministry of Health and Welfare, Korea Institute for Health and Social
Affairs. 2005 Survey report on the disabled. Ministry of Health and
Welfare, Korea Institute for Health and Social Affairs 2006.
19. Labor Statistics of Korea. 2005 Survey Report on Wage Structure.
Ministry of Labor 2007 April cited; Available from: http://labor-
stat.molab.go.kr
20. Goeree R, O’Brien BJ, Blackhouse G, Agro K, Goering P. The val-
uation of productivity costs due to premature mortality: a compari-
son of the human-capital and friction-cost methods for schizophre-
nia. Can J Psychiatry 1999; 44: 455-63.
21. Goeree R, Farahati F, Burke N, Blackhouse G, O’Reilly D, Pyne J,
Tarride JE. The Economic Burden of Schizophrenia in Canada in
2004. Curr Med Res Opin 2005; 21: 2017-28. In: Murray RM, Jones
PB, Susser E, Van Os J, Cannon M, editors. The epidemiology of
schizophrenia. New York, Cambridge University Press 2003.
22. Goeree R, Farahati F, Burke N, Blackhouse G, O'Reilly D, Pyne J,
Tarride JE. The economic burden of schizophrenia in Canada in
2004. Curr Med Res Opin 2005; 21: 2017-28.
23. Jeong HS. Public financing in total health expenditure and cover-
age by National Health Insurance in Korea: including comparison
with other OECD countries. Korean J Health Economics Policy
2004; 10: 95.
24. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disor-
der in the general population: results of The Netherlands Mental
Health Survey and Incidence Study (NEMESIS). Soc Psychiatry
Psychiatr Epidemiol 1998; 33: 587-95.
25. Cho MJ, Kim JK, Jeon HJ, Suh T, Chung IW, Hong JP, Bae JN, Lee
DW, Park JI, Cho SJ, Lee CK, Hahm BJ. Lifetime and 12-month
prevalence of DSM-IV psychiatric disorders among Korean adults. J
Nerv Ment Dis 2007; 195: 203-10.
26. Andrews G. The cost of schizophrenia revisited. Schizophr Bull 1991;
17: 389-94.
27. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene
A, Thornicroft G, Vazquez-Barquero JL, Knudsen HC, Becker T.
Comparing patterns and costs of schizophrenia care in five Euro-
pean countries: the EPSILON study. European Psychiatric Services:
Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand
2002; 105: 42-54.
28. DeFrances CJ, Hall MJ, Podgornik MN. Advance data from vital
and health statistics; no 359. Hyattsville, MD: National Center for
Health Statistics. 2005. 2003.
29. Australian Institute of Health and Welfare (AIHW). Australian hospi-
tal statistics 2001-02. AIHW cat. no. HSE 25. Canberra: AIHW (Health
Services Series no. 20) 2003.
30. Department of Health. Hospital Episode Statistics, Department of
Health, England, 2002-03.
174 S.M. Chang, S.-J. Cho, H.J. Jeon, et al.Cost of Schizophrenia in Korea 175
Indirect costs ($)=Q1+Q2+Q3+Q4
Productivity loss due to unemployment  Q1= Mjn×Njn×(Ojn-Pjn); n=age, j=gender
Mjn=general population annual average earnings by age and gender
Njn=number of persons with schizophrenia in Korea by age and gender
Ojn=general population employment rates by age and gender
Pjn=schizophrenia employment rates by age and gender
Productivity loss due to decreased annual earnings Q2 = Mjn×Ljn×R; n=age, j=gender
Mjn=general population annual average earnings by age and gender
Ljn=number of employed persons with schizophrenia by age and gender
R=productivity decrease ratio
Productivity loss due to premature death Q3 = jn×Yjn
t×pij×eij /(1+r)
n; n=age, j=gender, t=age at death
Fjn=number of deaths attributable to schizophrenia by age and gender
Yjn
t=annual average earnings after age at death by age and gender
pjn=labor force participation by age and gender
ejn=employment rate by age and gender
r=discount rate
Caregivers’ productivity loss Q4 =S×C×D×E
S=number of schizophrenia patients with disability
C=percentage of those with schizophrenia that interfered with caregivers’ earnings
D=care-giving time (month)
E=general population monthly average earnings
Equations for indirect costs
Appendix 1 